97 related articles for article (PubMed ID: 22161805)
1. A framework for joint modeling and joint assessment of efficacy and safety endpoints for probability of success evaluation and optimal dose selection.
He W; Cao X; Xu L
Stat Med; 2012 Feb; 31(5):401-19. PubMed ID: 22161805
[TBL] [Abstract][Full Text] [Related]
2. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
Kimani PK; Stallard N; Hutton JL
Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
[TBL] [Abstract][Full Text] [Related]
3. An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials.
Brutti P; Gubbiotti S; Sambucini V
Stat Med; 2011 Jun; 30(14):1648-64. PubMed ID: 21520453
[TBL] [Abstract][Full Text] [Related]
4. Assessing the success probability of a Phase III clinical trial based on Phase II data.
Su Z
Contemp Clin Trials; 2010 Nov; 31(6):620-3. PubMed ID: 20713180
[TBL] [Abstract][Full Text] [Related]
5. Risk management frameworks for human health and environmental risks.
Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
[TBL] [Abstract][Full Text] [Related]
6. Joint probability of statistical success of multiple phase III trials.
Zhang J; Zhang JJ
Pharm Stat; 2013; 12(6):358-65. PubMed ID: 24106067
[TBL] [Abstract][Full Text] [Related]
7. How modeling and simulation have enhanced decision making in new drug development.
Miller R; Ewy W; Corrigan BW; Ouellet D; Hermann D; Kowalski KG; Lockwood P; Koup JR; Donevan S; El-Kattan A; Li CS; Werth JL; Feltner DE; Lalonde RL
J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):185-97. PubMed ID: 16283534
[TBL] [Abstract][Full Text] [Related]
8. An adaptive dose-finding design incorporating both toxicity and efficacy.
Zhang W; Sargent DJ; Mandrekar S
Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
[TBL] [Abstract][Full Text] [Related]
9. Dose-finding design driven by efficacy in onco-hematology phase I/II trials.
Seegers V; Chevret S; Resche-Rigon M
Stat Med; 2011 Jun; 30(13):1574-83. PubMed ID: 21394754
[TBL] [Abstract][Full Text] [Related]
10. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
André FE; Foulkes MA
Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414
[TBL] [Abstract][Full Text] [Related]
11. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
12. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.
Nixon RM; O'Hagan A; Oakley J; Madan J; Stevens JW; Bansback N; Brennan A
Pharm Stat; 2009; 8(4):371-89. PubMed ID: 19340851
[TBL] [Abstract][Full Text] [Related]
13. A parallel phase I/II clinical trial design for combination therapies.
Huang X; Biswas S; Oki Y; Issa JP; Berry DA
Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495
[TBL] [Abstract][Full Text] [Related]
14. Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations.
Hammad TA; Pinheiro SP; Neyarapally GA
Clin Trials; 2011 Oct; 8(5):559-70. PubMed ID: 21878445
[TBL] [Abstract][Full Text] [Related]
15. Joint modeling of progression-free survival and death in advanced cancer clinical trials.
Dejardin D; Lesaffre E; Verbeke G
Stat Med; 2010 Jul; 29(16):1724-34. PubMed ID: 20572123
[TBL] [Abstract][Full Text] [Related]
16. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
De Ridder F
Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
[TBL] [Abstract][Full Text] [Related]
17. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
Citrome L
Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
[TBL] [Abstract][Full Text] [Related]
18. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
19. Analysis of longitudinal laboratory data in the presence of common selection mechanisms: a view toward greater emphasis on pre-marketing pharmaceutical safety.
Schildcrout JS; Jenkins CA; Ostroff JH; Gillen DL; Harrell FE; Trost DC
Stat Med; 2008 May; 27(12):2248-66. PubMed ID: 17929332
[TBL] [Abstract][Full Text] [Related]
20. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
